Despite positive clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial opposition from managed care entities. The insurers are typically creating obstacles to reimbursement, like high price requirements and prior authorization that restrict user opportunity. Analys… Read More